- ISIN CA24463V1013
- Country Canada
Latest Research
News Functions
Additional Functions
16 May 2022
Defence Therapeutics Inc.
Original-Research: Defence Therapeutics Inc. (von GBC AG): International Investment Forum
Defence Therapeutics Inc.
Original-Research: Defence Therapeutics Inc. (von GBC AG): International Investment Forum
15 February 2022
Defence Therapeutics Inc.
Original-Research: Defence Therapeutics Inc. (von GBC AG): Kaufen
14 February 2022
Defence Therapeutics Inc.
Original-Research: Defence Therapeutics Inc. (von GBC AG): Kaufen
Defence Therapeutics Inc.
Original-Research: Defence Therapeutics Inc. (von GBC AG): BUY
10 February 2022
Defence Therapeutics Inc.
Original-Research: Defence Therapeutics Inc. (von GBC AG): BUY
25 January 2022
Defence Therapeutics Inc.
Original-Research: Defence Therapeutics Inc. (von GBC AG): –
24 January 2022
Defence Therapeutics Inc.
Original-Research: Defence Therapeutics Inc. (von GBC AG): –
7 December 2021
Defence Therapeutics Inc.
Original-Research: Defence Therapeutics Inc. (von GBC AG): Management Interview
6 December 2021
Defence Therapeutics Inc.
Original-Research: Defence Therapeutics Inc. (von GBC AG): Management Interview
Latest News
News Functions
Additional Functions
2 May 2024
Defence Therapeutics Inc.
PANKREASKREBS: ERFOLGREICHER TEST ZUR BEKÄMPFUNG VON PANKREASKREBS MIT DEM ARM-002-IMPFSTOFF VON DEFENCE
Defence Therapeutics Inc.
PANCREACTIC CANCER: SUCCESFUL TRIAL AGAINST PANCREATIC CANCER WITH DEFENCE’S ARM-002 ANTI-CANCER VACCINE
23 April 2024
Defence Therapeutics Inc.
DER ACCUTOX ARM-002-IMPFSTOFF ZUR KREBSBEKÄMPFUNG FÜHRT ZU EINER HOCHWIRKSAMEN ANTIGENPRÄSENTATION
Defence Therapeutics Inc.
DEFENCE’S ACCUTOX ANTI-CANCER ARM-002 VACCINE EXHIBITS POTENT ANTIGEN PRESENTATION
17 April 2024
Defence Therapeutics Inc.
DEFENCE THERAPEUTICS SIGNS WITH GERMAN BASED FMS CONSULT GMBH FOR FINANCING STRATEGY TO SUPPORT DEFENCE PIPELINE GROWTH
26 March 2024
Defence Therapeutics Inc.
ERFOLGE VON DEFENCE BEI SEINEM ACCUTOX®-ARM(TM)-VAKZIN ZUR KREBSBEKÄMPFUNG FÜHREN ZUR ENTWICKLUNG EINES WIRKUNGSVOLLEN ARM-002(TM)-KREBSIMPFSTOFFS DER ZWEITEN GENERATION